Adherence and Persistence with Once-daily Teriparatide in Japan: a Retrospective, Prescription Database, Cohort Study

Overview

Journal J Osteoporos

Publisher Wiley

Specialty Orthopedics

Date 2014 Jan 24

PMID 24455412

Citations 12

Authors

Ikuko Tanaka

Masayo Sato

Tomoko Sugihara

Douglas E Faries

Shuko Nojiri

Peita Graham-Clarke

Jennifer A Flynn

Russel T Burge

Affiliations

Soon will be listed here.

Abstract

Adherence and persistence with osteoporosis treatments are essential for reducing fracture risk. Once-daily teriparatide is available in Japan for treating osteoporosis in patients with a high risk of fracture. The study objective was to describe real-world adherence and persistence with once-daily teriparatide 20 μg during the first year of treatment for patients who started treatment during the first eight months of availability in Japan. This prescription database study involved patients with an index date (first claim) between October 2010 and May 2011, a preindex period ≥6 months, and a postindex period ≥12 months and who were aged >45 years. Adherence (medication possession ratio (MPR)) and persistence (time from the start of treatment to discontinuation; a 60-day gap in supply) were calculated. A total of 287 patients started treatment during the specified time period; 123 (42.9%) were eligible for inclusion. Overall mean (standard deviation) adherence was 0.702 (0.366), with 61.0% of patients having high adherence (MPR > 0.8). The percentage of patients remaining on treatment was 65.9% at 180 days and 61.0% at 365 days. Our findings suggest that real-world adherence and persistence with once-daily teriparatide in Japan are similar to that with once-daily teriparatide in other countries and with other osteoporosis medications.

Citing Articles

Drug utilization pattern of romosozumab and other osteoporosis treatments in Japan, 2019-2021.

Soen S, Wang A, Hamaya E, Chien H, Lin T J Bone Miner Metab. 2024; 42(6):653-667.

PMID: 38987505 PMC: 11631996. DOI: 10.1007/s00774-024-01530-6.

Effects of Teriparatide on Bone Mineral Density and Prevention of Fragility Fractures in Saudi Arabian Subjects with Osteoporosis: A Two-Year Clinical Study from a Single Center.

Sadat-Ali M, Al-Omran A, AlTabash K, Aldakheel D, Elansassy S, Hegazi T Int J Clin Pract. 2022; 2022:3779745.

PMID: 36380751 PMC: 9626192. DOI: 10.1155/2022/3779745.

Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan.

Mori T, Crandall C, Fujii T, Ganz D Arch Osteoporos. 2021; 16(1):72.

PMID: 33866457 PMC: 8053143. DOI: 10.1007/s11657-021-00891-z.

Understanding the factors associated with initiation and adherence of osteoporosis medication in Japan: An analysis of patient perceptions.

Orimo H, Sato M, Kimura S, Wada K, Chen X, Yoshida S Osteoporos Sarcopenia. 2019; 3(4):174-184.

PMID: 30775527 PMC: 6372844. DOI: 10.1016/j.afos.2017.10.002.

A systematic review of factors affecting medication adherence among patients with osteoporosis.

Yeam C, Chia S, Tan H, Kwan Y, Fong W, Seng J Osteoporos Int. 2018; 29(12):2623-2637.

PMID: 30417253 DOI: 10.1007/s00198-018-4759-3.

References

Miyakoshi N, Itoi E, Kobayashi M, Kodama H . Impact of postural deformities and spinal mobility on quality of life in postmenopausal osteoporosis. Osteoporos Int. 2003; 14(12):1007-12. DOI: 10.1007/s00198-003-1510-4. View

Mulgund M, Beattie K, Wong A, Papaioannou A, Adachi J . Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture. Ther Adv Musculoskelet Dis. 2012; 1(1):5-11. PMC: 3382667. DOI: 10.1177/1759720X09339551. View

Cramer J, Roy A, Burrell A, Fairchild C, Fuldeore M, Ollendorf D . Medication compliance and persistence: terminology and definitions. Value Health. 2008; 11(1):44-7. DOI: 10.1111/j.1524-4733.2007.00213.x. View

Ziller V, Zimmermann S, Kalder M, Ziller M, Seker-Pektas B, Hellmeyer L . Adherence and persistence in patients with severe osteoporosis treated with teriparatide. Curr Med Res Opin. 2010; 26(3):675-81. DOI: 10.1185/03007990903538409. View

Gold D, Alexander I, Ettinger M . How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Ann Pharmacother. 2006; 40(6):1143-50. DOI: 10.1345/aph.1G534. View

Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E . Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab. 2007; 25(5):302-9. DOI: 10.1007/s00774-007-0768-6. View

Miyakoshi N, Hongo M, Maekawa S, Ishikawa Y, Shimada Y, Itoi E . Back extensor strength and lumbar spinal mobility are predictors of quality of life in patients with postmenopausal osteoporosis. Osteoporos Int. 2007; 18(10):1397-403. DOI: 10.1007/s00198-007-0383-3. View

Silverman S, Gold D . Compliance and persistence with osteoporosis medications: a critical review of the literature. Rev Endocr Metab Disord. 2010; 11(4):275-80. PMC: 3028075. DOI: 10.1007/s11154-010-9138-0. View

Arden N, Earl S, Fisher D, Cooper C, Carruthers S, Goater M . Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int. 2006; 17(11):1626-9. DOI: 10.1007/s00198-006-0171-5. View

10.

Solomon D, Avorn J, Katz J, Finkelstein J, Arnold M, Polinski J . Compliance with osteoporosis medications. Arch Intern Med. 2005; 165(20):2414-9. DOI: 10.1001/archinte.165.20.2414. View

11.

Fujiwara S, Hamaya E, Goto W, Masunari N, Furukawa K, Fukunaga M . Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk in Japan. Bone. 2011; 49(3):520-5. DOI: 10.1016/j.bone.2011.05.021. View

12.

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

13.

Weycker D, Macarios D, Edelsberg J, Oster G . Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int. 2006; 17(11):1645-52. DOI: 10.1007/s00198-006-0179-x. View

14.

Oinuma T, Sakuma M, Endo N . Secular change of the incidence of four fracture types associated with senile osteoporosis in Sado, Japan: the results of a 3-year survey. J Bone Miner Metab. 2009; 28(1):55-9. DOI: 10.1007/s00774-009-0097-z. View

15.

Kothawala P, Badamgarav E, Ryu S, Miller R, Halbert R . Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007; 82(12):1493-501. DOI: 10.1016/S0025-6196(11)61093-8. View

16.

Lekkerkerker F, Kanis J, Alsayed N, Bouvenot G, Burlet N, Cahall D . Adherence to treatment of osteoporosis: a need for study. Osteoporos Int. 2007; 18(10):1311-7. DOI: 10.1007/s00198-007-0410-4. View

17.

Hagino H, Furukawa K, Fujiwara S, Okano T, Katagiri H, Yamamoto K . Recent trends in the incidence and lifetime risk of hip fracture in Tottori, Japan. Osteoporos Int. 2008; 20(4):543-8. DOI: 10.1007/s00198-008-0685-0. View

18.

Orimo H, Yaegashi Y, Onoda T, Fukushima Y, Hosoi T, Sakata K . Hip fracture incidence in Japan: estimates of new patients in 2007 and 20-year trends. Arch Osteoporos. 2010; 4(1-2):71-77. PMC: 2836738. DOI: 10.1007/s11657-009-0031-y. View

19.

Cramer J, Amonkar M, Hebborn A, Altman R . Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005; 21(9):1453-60. DOI: 10.1185/030079905X61875. View

20.

Siris E, Harris S, Rosen C, Barr C, Arvesen J, Abbott T . Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81(8):1013-22. DOI: 10.4065/81.8.1013. View